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Abstract
Background: Relapse in schizophrenia is a major cause of distress and disability and is predicted by changes in symptoms such
as anxiety, depression, and suspiciousness (early warning signs [EWSs]). These can be used as the basis for timely interventions
to prevent relapse. However, there is considerable uncertainty regarding the implementation of EWS interventions.
Objective: This study was designed to establish the feasibility of conducting a definitive cluster randomized controlled trial
comparing Early signs Monitoring to Prevent relapse in psychosis and prOmote Well-being, Engagement, and Recovery
(EMPOWER) against treatment as usual (TAU). Our primary outcomes are establishing parameters of feasibility, acceptability,
usability, safety, and outcome signals of a digital health intervention as an adjunct to usual care that is deliverable in the UK
National Health Service and Australian community mental health service (CMHS) settings. We will assess the feasibility of
candidate primary outcomes, candidate secondary outcomes, and candidate mechanisms for a definitive trial.
Methods: We will randomize CMHSs to EMPOWER or TAU. We aim to recruit up to 120 service user participants from 8
CMHSs and follow them for 12 months. Eligible service users will (1) be aged 16 years and above, (2) be in contact with local
CMHSs, (3) have either been admitted to a psychiatric inpatient service or received crisis intervention at least once in the previous
2 years for a relapse, and (4) have an International Classification of Diseases-10 diagnosis of a schizophrenia-related disorder.
Service users will also be invited to nominate a carer to participate. We will identify the feasibility of the main trial in terms of
recruitment and retention to the study and the acceptability, usability, safety, and outcome signals of the EMPOWER intervention.
EMPOWER is a mobile phone app that enables the monitoring of well-being and possible EWSs of relapse on a daily basis. An
algorithm calculates changes in well-being based on participants’ own baseline to enable tailoring of well-being messaging and
clinical triage of possible EWSs. Use of the app is blended with ongoing peer support.
Results: Recruitment to the trial began September 2018, and follow-up of participants was completed in July 2019. Data
collection is continuing. The database was locked in July 2019, followed by analysis and disclosing of group allocation.
Conclusions: The knowledge gained from the study will inform the design of a definitive trial including finalizing the delivery
of our digital health intervention, sample size estimation, methods to ensure successful identification, consent, randomization,
and follow-up of participants, and the primary and secondary outcomes. The trial will also inform the final health economic model
to be applied in the main trial.
Trial Registration: International Standard Randomized Controlled Trial Number (ISRCTN): 99559262;
http://isrctn.com/ISRCTN99559262
International Registered Report Identifier (IRRID): DERR1-10.2196/15058
(JMIR Res Protoc 2020;9(1):e15058)  doi: 10.2196/15058
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Introduction
Background
Relapse influences the long-term course of psychosis with rates
identified as 28% (range 12%-47%), 43% (range 35%-54%),
54% (range 40%-63%) at 1, 1.5, 2, and 3 years follow-up,
respectively [1], and more recent evidence shows similar relapse
rates [2,3]. Relapse is also associated with poorer response to
subsequent antipsychotic treatment [4]. Relapses can occur in
up to 80% of participants at the 10-year follow-up [5] and can
lead to higher inpatient and outpatient costs [6].
One important predictor of relapse is lack of acceptance of
treatment and unplanned discontinuation of antipsychotic
medication [1]. Poorer adherence often signals a lack of
engagement with services and failure of services to build a
collaborative working alliance [7]. Nonadherence to
antipsychotic treatment is predicted by poorer insight, previous
experience of involuntary treatment, poorer premorbid
functioning, comorbid substance misuse, forensic history, poor
relationship with the prescriber, greater deprivation, and transfer
to secondary care [8-10]. Relapse itself is an important marker
of the severity and complexity of illness and is predicted by
previous suicide attempts [11]; depression, hostility, and
embarrassment [12]; poorer premorbid functioning; family
criticism; substance misuse; social isolation [1]; and negative
interpersonal style (possibly linked to poorer utilization of social
support) [13].
Birchwood et al [14] pioneered the development of systematic
early signs monitoring for relapse and its integration into routine
care. It is now known that relapse is the culmination of a process
of changes that commence days and sometimes weeks before
psychosis symptoms reemerge or are exacerbated. These early
warning signs (EWSs) include affective changes and incipient
psychosis. These EWSs can be detected as early as 8 weeks
before rehospitalization [15]. A systematic review [16] found
that the sensitivity of early signs to relapse (proportion of
relapses correctly predicted) ranged from 10% to 80% (median
61%) and specificity (proportion of nonrelapses correctly
identified) ranged from 38% to 100% (median 81%). Detection
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of relapse was improved by more frequent monitoring (at least
fortnightly) and by the inclusion of both psychotic and affective
symptoms.
A significant barrier to relapse prevention is fear of help seeking
arising from previous experiences of relapse [17]. For example,
people may avoid calling their care coordinator in the context
of an increase in EWSs for fear of being admitted to the hospital.
Research has demonstrated that fear of relapse is linked to more
traumatic experiences of psychosis and hospital admission and
greater fear of symptoms, such as voices and paranoia [18]. In
a randomized controlled trial (RCT) of relapse detection, fear
of relapse contributed independently to the prediction of relapse
(sensitivity=72%, 95% CI 52-86; specificity=46%, 95% CI
32-60) compared with EWSs (sensitivity=79%, 95% CI 62-89;
specificity=35%, 95% CI 23-50). Fear of recurrence was also
associated with greater depression, feelings of entrapment,
self-blame, and shame [19]. Therefore, it is important to include
fear of recurrence in the monitoring of EWSs.
Fear of illness and stigma are closely related to emotional
distress [20] and to poorer insight into schizophrenia [8].
Feelings of fear, depression, and helplessness are common
emotional experiences before full relapse [21]. In an effort to
minimize the stigma of illness and prevent relapse, people can
adopt avoidant coping styles that are associated with increased
risk of relapse [20]. These coping styles are associated with
greater insecurity in relationships, lower self-esteem, lower
levels of adherence, and reluctance to seek help in a crisis.
Reluctance to seek help may result from greater fear of relapse
arising from experiences of involuntary admission. In this sense,
avoidance of help seeking can be understood from the
perspective that people with experience of psychosis are
attempting to minimize or avert the adverse consequences of
help seeking based on their lived experience. A recent systematic
review [22] found that greater difficulties in forming
relationships were associated with poorer engagement with
services, more problematic relationships with staff, and more
frequent and longer hospital admissions. In sum, the detection
of and action following EWSs may be constrained by poor
relationships between service providers and people using
services, avoidance of help seeking, perceived stigma, fear of
relapse, and reluctance to disclose EWSs.
A Cochrane review focused on the effectiveness of interventions
targeting recognition and management of EWSs of relapse in
schizophrenia [23]. Significant effects in favor of EWS
interventions were found for the number of participants relapsing
(15 RCTs; n=1502; risk ratio [RR] 0.53, 95% CI 0.36-0.79) and
the number of participants being rehospitalized (15 RCTs;
n=1457; RR 0.48, 95% CI 0.35-0.66); however, the
methodological quality of the trials was poor in terms of
randomization, concealment, and blindness. Future EWS
interventions need to address these methodological problems
that limit their generalizability to usual care. Until this happens,
EWS interventions cannot be recommended for routine
implementation in health services [23].
An important aspect of service provision for those people at
greatest risk of relapse is having access to an integrated mental
health care system that enables clear shared planning for
managing risk and relapse prevention. One example of this is
the role of joint crisis plans (JCPs) in the United Kingdom. The
CRIMSON study [24] was an individual-level RCT that
compared the effectiveness of JCPs with treatment as usual
(TAU) for people with a diagnosis of schizophrenia. There was
no significant impact on the primary outcome (reduced coercion
into hospital). It was noted that when faced with crisis, in spite
of the considerable effort in developing the JCP with service
users, the teams reverted to custom and practice. The staff did
not consult JCPs in planning the team response to a crisis.
Furthermore, people in receipt of services experienced an
inability to influence clinicians’ behaviors, and this was
interpreted as signaling a lack of respect for their views and
opinions. Consequently, they described their interactions with
clinicians as playing the game, that is, appearing to comply with
treatment decisions. Clinicians themselves experienced their
interactions with people using services as ritualized, especially
in the context of responding to increased risk [25].
Gumley and Park [17] highlighted that relapse prevention based
on EWS monitoring relies on the person receiving services
initiating help seeking in the context of feeling vulnerable and
threatened. Many individuals find help seeking a challenge and
may have had difficult or traumatic experiences of psychosis.
Delay in help seeking narrows the window of opportunity for
successful relapse prevention, which in turn increases reliance
on coercive measures confirming pre-existing negative
expectations. It is therefore essential to develop and evaluate
an intervention that can facilitate safe and honest disclosure of
possible EWSs while also reorienting the response of mental
health teams and the actions of their staff in a crisis toward a
more collaborative approach.
Our conceptual framework for improving relapse detection and
prevention aims to understand how EWSs unfold in the context
of important caring relationships. Figure 1 provides an
illustration of our cognitive interpersonal model for EWSs. Fear
of recurrence drives feelings of fear, anxiety, and shame. Coping
strategies to regulate emotional distress (eg, increased
hypervigilance, worrying, and avoidance) shape care providers’
own cognitive and emotional responses to perceived increased
risk of relapse. For example, care providers may interpret
increased emotional distress or avoidance (eg, cancelling
appointments) as evidence of increased risk prompting changes
in clinical care and risk management. These changes may further
confirm individuals’ negative expectations of services and fear
of recurrence. Therefore, interventions that can enhance positive
emotional awareness (through self-monitoring), choice and
autonomy (through self-management promotion), and improved
communication (through increased understanding) could provide
a means to disrupt and change negative interpersonal cycles.
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Figure 1. Cognitive interpersonal framework for early warning signs.
Digital technology has the potential to offer a step change that
can influence early signs monitoring both for people receiving
and providing mental health services [26,27]. Mobile phones
to support health care are promising for the delivery of
interventions that are unconstrained by the limitations of existing
treatment settings. Mobile phones are widely available and are
continuously dropping in cost, and nearly 3 billion people are
projected to own a mobile phone by 2020 [28]. Mobile phone
ownership among people who experience psychosis is increasing
with estimated rates of ownership from 66.4% (95% CI
54.1%-77.6%) rising to 81.4% (n=454) in more recent studies
[29]. Furthermore, people with psychosis express an interest in
the use of mobile phones to enhance contact with services and
to support self-management [29,30]. Mobile phones, particularly
mobile phones, offer opportunities for ecological momentary
assessment (EMA) to collect data on repeated occasions, in real
time, and in the context of daily life [31]. This enhances the
ability to assess individuals in their usual context, temporally
close to relevant events, and intensively and repeatedly as
psychological processes unfold over time [32]. Bell et al [33]
found that across 9 interventions (n=459), interventions for
people with psychosis using EMA show satisfactory levels of
feasibility and acceptability as well as preliminary evidence of
improved clinical outcomes. Furthermore, studies that
prospectively assess symptom course using mobile phone apps
in people with psychosis show promise [34-45] in terms of
feasibility of, acceptability of, and adherence to regular daily
monitoring and also delivery of in-time interventions to support
coping [36] or delivery of cognitive behavioral therapy [38].
However, studies employing mobile phones to promote relapse
detection and intervention are not without their challenges. The
Information Technology–Aided Relapse Prevention Program
in Schizophrenia (ITAREPS) utilized a weekly text-based
monitoring system to detect EWSs in people with psychosis.
This system gathers data on early signs of psychosis using text
messaging with clinicians notified by alerts where scores breach
a specified threshold. Treating clinicians are expected to increase
medication by 20% within 24 hours of an alert. In the initial
studies [46,47], adherence by people using services and family
members was problematic, in that only 47% were described as
high users with 70% return rates. In the ITAREPS RCT [48],
trial adherence improved; however, adherence to the treatment
protocol was problematic at 39% largely owing to conflicts
between protocol-indicated medication increases and
psychiatrists’ clinical judgment. Komatsu et al [49] found that
adherence to the ITAREPS protocol was improved when mental
health nurses were involved in triaging EWS assessments. More
recently, Eisner et al [50] demonstrated that over 6 months,
adherence to mobile phone-based assessments of EWSs was
65% and successfully predicted increased psychotic symptoms
3 weeks later.
In sum, mobile phone technology offers a significant opportunity
to deliver EMA-based monitoring of changes in well-being that
are ecologically valid and contextually sensitive. Preliminary
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studies show encouraging levels of user acceptability and
engagement, and thus, they offer the potential to recognize
EWSs and activate timely assessment and intervention to
promote self-management and relapse prevention. However,
there are important implementation challenges to ensure that
these technologies can enhance relationships and shared decision
making, particularly during times of increased stress and crisis.
Objectives
The overall aim of this study is to establish the feasibility of
conducting a definitive cluster randomized controlled trial
(cRCT) comparing Early signs Monitoring to Prevent relapse
in psychosis and prOmote Well-being, Engagement, and
Recovery (EMPOWER) against TAU. We will establish the
parameters of the feasibility, acceptability, usability, safety, and
outcome signals of an intervention as an adjunct to usual care
that is easily deliverable in the National Health Service (NHS)
and Australian community mental health service (CMHS)
settings. The EMPOWER intervention aims (1) to enhance the
recognition of EWSs by people using services and their carers
and (2) to provide a stepped-care pathway that is either
self-activated or in liaison with a carer and/or community health
care professional, which then (3) triggers a relapse prevention
strategy that can be stepped up to a whole team response to
reduce the likelihood of a psychotic relapse.
Specifically, we aim to do the following:
1. Enhance and tailor our mobile phone software app to deliver
EWS monitoring, self-management interventions, and
access to a relapse prevention pathway that is firmly
embedded in whole team protocols and action.
2. Determine rates of eligibility, consent, and recruitment of
potentially eligible participants (people using services,
carers, and care coordinators) to the study.
3. Assess the performance and safety of the EMPOWER Class
1 Medical Device (CI/2017/0039).
4. Assess the feasibility, acceptability, and usability of the
intervention including feedback on suggested enhancements
from people receiving the intervention, peer support
workers, and clinicians.
5. Assess primary and secondary outcomes to determine
preliminary signals of efficacy of the EMPOWER Relapse
Prevention Intervention as a basis for the estimation of
sample size requirements of a future definitive trial.
6. Undertake a qualitative analysis of relapses to refine the
intervention in the main trial.
7. Establish the study parameters and data-gathering
frameworks required for a coordinated health economic
evaluation of a full trial across the United Kingdom and
Australia.
Methods
Trial Design
We will evaluate EMPOWER using a multicenter, 2-arm,
parallel group cRCT involving 8 purposively selected CMHSs
(2 in Melbourne, Australia, and 6 in Glasgow, Scotland) with
12-month follow-up. The CMHS will be the unit of
randomization (the cluster), with the intervention delivered by
the teams to people using services and with outcomes assessed
within these clusters. The Standard Protocol Items:
Recommendations for Interventional Trials checklist is provided
as an additional file. The study is planned and implemented in
concordance with the Consolidated Standards of Reporting
Trials (CONSORT) cluster trial extension [51] and the extension
to randomized pilot and feasibility trials [52]. We chose a cluster
design as the EMPOWER intervention aims to enable a
team-based response to people in receipt of services whose
real-time EWS monitoring has activated a relapse prevention
pathway. Our CONSORT diagram is detailed in Figure 2.
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Figure 2. Consolidated Standards of Reporting Trials flow diagram. TAU: treatment as usual.
Ethics and Governance
The West of Scotland Research Ethics Service (GN16MH271
Ref: 16/WS/0225) and Melbourne Health Human Research
Ethics Committee (HREC/15/MH/344) approved the study. The
study sponsors are NHS Greater Glasgow & Clyde in the United
Kingdom and North Western Mental Health in Australia.
Approvals from the NHS Health Research Authority and a
notice of no objection for a trial of a medical device
(CI/2017/0039) from the United Kingdom’s Medicines and
Health care products Regulatory Agency (MHRA) was also
received for the trial, and it has been prospectively registered
(ISRCTN99559262). The basic trial methods of enrolment,
interventions, and assessments are summarized in Table 1.
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Table 1. Participant timeline.
Study period and time pointAssessment timeline
Close-out (12
months)
Post allocationAllocation (0
months)
Enrolment (baseline)
6 months3 months
Enrolment
———
—
bXaEligibility screen
————XInformed consent
———X—Allocation
Intervention
XXX——EMPOWERc
Service u ser assessments
XXX—XFeasibility
XXX—Acceptability and usability
XXX—XRemission status
XXX—Relapse
XXX—XPositive and Negative Syndrome Scale
XXX—XPersonal and Social Performance Scale
XXX—XCalgary Depression Scale for Schizophrenia
XXX—XTime Line Follow Back
XXX—XHospital Anxiety and Depression Scale
XXX—XPersonal Beliefs about Illness Questionnaire
XXX—XService Attachment Scale
XXX—XMedication Adherence Rating Scale
XXX—XEuroQol 5 Dimension
XXX—XAssessment of quality of life
XXX—XRUQd
XXX—XQuestionnaire for Personal Recovery
XXX—XGeneralized Self Efficacy Scale
XXX—XPsychosis Attachment Measure
XXX—XPerceived Criticism and Warmth Measure
Carer assessments
XXX—XFeasibility
XXX—XCarer Quality of Life 7 Dimension
XXX—XEuroQol 5 Domain 5 Level
XXX—XResource Use Questionnaire
XXX—XPerceived Criticism and Warmth Measure
XXX—XInvolvement Evaluation Questionnaire
Care coordinator
XXX—XFeasibility
XXX—XService Engagement Scale
aItem was applicable at the relevant study time point.
bItem was not applicable at the relevant study time point.
cEMPOWER: Early signs Monitoring to Prevent relapse in psychosis and prOmote Well-being, Engagement, and Recovery.
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Preliminary Work—Patient and Public Involvement
At the outset of the study, we conducted extensive consultation
with key stakeholders including mental health staff (n=88),
people with lived experience (n=21), and carers (n=40) in a
series of 25-focus groups across Glasgow and Melbourne. The
stakeholder consultation shaped the development of the
EMPOWER intervention [53]. The Scottish Recovery Network
also played a key role in shaping further consultation with
people with lived experience in further refining the intervention
development and planning.
Eligibility Criteria
Participation will be sought from CMHS in NHS Greater
Glasgow & Clyde in the United Kingdom and North Western
Mental Health Services in Melbourne, Australia. All participants
(mental health staff, service users, and carers) will be
approached for their informed and written consent before
assessment and randomization. Research assistants (RAs) will
be responsible for recruitment and written informed consent.
Recruitment took place between September 2018 and July 2019.
Final follow-up assessments were completed end of June 2019.
Community Mental Health Services
We will likely engage CMHSs to have 5 or more care
coordinators willing to participate for a period of 12 months
and where potential care coordinators having eligible service
users on their caseload being likely to consider participation.
Service Users
Service users from participating CMHSs are eligible for
inclusion if they are adults (aged 16 years and above); are in
contact with a local CMHS; have either been admitted to a
psychiatric inpatient service at least once in the previous 2 years
for a relapse of psychosis or received crisis intervention (eg,
via a crisis intervention service, reengaged with a CMHS) in
the previous 2 years for a relapse of psychosis; have received
a diagnosis of schizophrenia-related disorder, specifically 295.40
schizophreniform disorder (International Classification of
Diseases-10 [ICD10]=F20.81), 295.70 schizoaffective disorder
(ICD10=F25), 295.90 schizophrenia (ICD10=F20.9), 297.10
delusional disorder (ICD10=F22); and are able to provide
informed consent as adjudged by the care coordinator, if in
doubt, the responsible consultant.
Carers
Carers of people receiving support from participating CMHSs
will be eligible for inclusion if they have been nominated by
eligible participants; they are in regular contact with the person
receiving services; and they provide informed consent to
participate in the study.
Exclusion Criteria
Individuals will be ineligible for participation if they do not
meet the inclusion criteria outlined above. In addition,
participants will be excluded if they have experienced a recent
relapse operationally defined as having been discharged from
the care of a crisis team or psychiatric inpatient service within
the previous 4 weeks.
Interventions
In describing the EMPOWER intervention in the following
section, we have utilized the Template for Intervention
Description and Replication Checklist [54].
Early Signs Monitoring to Prevent Relapse in Psychosis
and Promote Well-being, Engagement, and Recovery
Intervention
Rationale
The rationale for the EMPOWER intervention was informed
by the cognitive interpersonal model outlined in Figure 1 and
has been designed to enable participants to daily monitor
changes in their well-being. In EMPOWER, we refer to changes
in well-being as ebb and flow as a means of moving away from
risk-orientated monitoring that can sensitize individuals to
increased fear of relapse. The terminology also conveys a
normalizing framework for understanding changes in emotions
and psychotic experiences in daily life. The EMPOWER
intervention is blended with peer support. A peer support worker
(PSW) is involved in setting up and personalizing the daily
questionnaire, alongside regular fortnightly follow-up. Clinical
triage of changes in well-being that are suggestive of EWSs is
enabled through an EMPOWER algorithm that triggers a check
in prompt (ChIP). This enables prompt identification of EWSs
and triggers a relapse prevention pathway.
The EMPOWER app was developed through consultation with
people using services, their carers, and mental health
professionals. Service user participants have access to the
EMPOWER app for up to 12 months of the intervention period.
EMPOWER was developed as a flexible user-led tool to (1)
daily monitor the ebb and flow of changes in their well-being
which incorporates, (2) personalized EWS items, (3) enables
the delivery of EMPOWER (self-management) messages
directly to service users and, (4) provides a mobile phone user
interface to enable service users to review their own data and
keep a diary of their experiences.
Materials
Daily monitoring of well-being is initiated by pseudorandom
mobile phone notifications to complete the EMPOWER
questionnaire. The questionnaire contains 22 items reflecting
13 domains (eg, mood, anxiety, coping, psychotic experiences,
self-esteem, connectedness to others, fear of relapse, and
personalized EWSs). Items include both positive (eg, “I’ve been
feeling close to others”) and negative (eg, “I’ve been worrying
about relapse”) content. Each item is completed using a simple
screen swipe that enables quick and efficient completion by
users. Each item is automatically scored on a scale of 1 to 7.
Where particular items score >3, users are invited to complete
supplementary questions to enable a more fine-grained
assessment of that domain. This provides up to a maximum of
56 questionnaire items. The questionnaire was piloted among
7 participants for an average of 36.7 days (range 32-49), and
the app was completed on an average of 24.5 days (range 16-35),
giving an overall rate of engagement of 68.9%.
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Procedures
A PSW meets with participants on an individual basis to
introduce the rationale for using the app, collaboratively sets
up the app on their own or a study mobile phone, and supports
the individual’s familiarization with the handset and app
functions. Participants are invited to choose up to 3 personalized
EWS items to be included in the EMPOWER questionnaire,
and further personalization of delusion specific items can also
be made. Where possible, an individual’s care coordinator and
nominated carer are invited to contribute to this meeting.
Participants are invited to undertake daily monitoring for an
initial 4-week baseline period to help establish their personal
baseline of the ebb and flow of their well-being. During this
period, additional support is provided by PSWs through weekly
telephone follow-up. This provides an opportunity to encourage
usage of the app, solve any technical problems, and identify
any adverse effects. At the end of the 4 weeks, a further meeting
is arranged with a PSW or mental health nurse to review
monitoring, encourage engagement with EMPOWER messages,
agree participants’ preferences for actions in response to changes
in well-being that are suggestive of EWSs and encourage
continued utilization of local CMHSs for clinical care. All
participants are offered ongoing fortnightly PSW support to
encourage use of the app: to support their reflection on changes
in well-being and their broader context including, for example,
stressful life events, and to encourage use of self-management
strategies prompted by EMPOWER messages.
Digital Procedures
The analysis and handling of questionnaire data is governed by
the EMPOWER algorithm. The EMPOWER algorithm is a
Class 1 Medical Device (ISO 14155:2011[E]), which is an
algorithm that forms one part of a broader system that is
designed to identify and respond to changes in well-being that
are suggestive of EWSs. Figure 3 provides a graphical
representation of the system’s high-level components and data
flow.
Figure 3. Early signs monitoring to prevent relapse in psychosis and promote well-being, engagement, and recovery system.
Participants use a mobile phone app that prompts them to answer
a daily questionnaire about potential EWSs of psychosis. The
data are then submitted to the EMPOWER server and analyzed
by the EMPOWER algorithm. The algorithm compares a
participant’s latest data entry against their personal baseline. If
changes exceed predefined thresholds, a ChIP is generated for
the participant. The consequences of the ChIP are that the
research team, which includes a registered mental health nurse
(in the United Kingdom), clinical psychologists (United
Kingdom and Australia), and general psychologist (Australia
only), is emailed about the participant and that the participant’s
status is set to alert and is highly visible on a secure Web-based
researcher interface. In addition to viewing and handling ChIPs,
researchers can also view longitudinal graphs of their
participants’ well-being and possible EWSs, filtered by question
or by domain (group of questions). In response to ChIPs, a
member of the research team checks in with the participant and
based on the outcome of this triage assessment, they can share
an update with the participants’ care coordinator who can, if
indicated, escalate increased support to the participant from
their local CMHS to reduce risk of relapse. These actions are
agreed on a case-by-case basis, and we did not constrain the
service user’s treatment provider to respond within a specific
timeframe or indeed in a specific way. We have undertaken the
responsibility to update the individual on any ongoing actions.
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The EMPOWER algorithm also runs a separate process scan
for EWS changes against the baseline. On the basis of these
changes, the logic selects a message from the most appropriate
of several content-based message pools (ie, one message pool
contains helpful messages about mood and another about anxiety
and coping). This message is delivered back to, and displayed
on, the participant’s EMPOWER app. Messages are intended
to help people have a greater sense of control over their mental
health and well-being and to support self-management.
Training and Support to Community Mental Health Service
Staff
Following randomization of CMHSs to EMPOWER, we will
aim to provide training to mental health staff in those teams
based on our model of relapse prevention, which emphasizes
(1) therapeutic alliance, (2) barriers to help seeking, (3)
familiarization with app, (4) developing an individualized
formulation of risk of relapse, and (5) developing a collaborative
relapse prevention plan. Following this, we aim to meet with
care coordinators on a fortnightly basis to provide support in
the implementation of EMPOWER. These meetings are aimed
to clarify and encourage formulation of any changes and
participants’ responses within the model and support clinicians
to consider EMPOWER-consistent intervention options.
Treatment as Usual Control
TAU was chosen as a control condition in both the Glasgow
and Melbourne centers as this provides a fair comparison with
routine clinical practice. In Glasgow and Melbourne, secondary
care is delivered by adult CMHSs, which largely involve regular,
fortnightly, or monthly follow-up with a care coordinator and
regular review by a psychiatrist. TAU is the modal comparison
for digital interventions in schizophrenia. However, recent trials
[38] have included active monitoring control groups. Our
comparison with TAU will be reviewed before submitting the
main trial application.
Outcomes
All outcome measures will be administered at baseline and
subsequently at 3, 6, and 12 months by RAs who will have been
trained in the use of all the instruments and scales and who have
achieved a satisfactory level of interrater reliability. RAs have
as a minimum a strong honors degree in Psychology or a related
discipline. Regular interrater reliability assessments will be
conducted during the trial. RAs will enter anonymized
participant data onto an electronic case record form hosted by
the University of Aberdeen, with the exception of relapse data.
Relapse data will be entered by the trial manager (SB). Data
quality and error checking will be conducted at each time point
including baseline, 3 months, 6 months, and 12 months post
randomization.
Primary Outcomes
Feasibility
For all participants, outcome assessment will include the
proportion of eligible and willing service users who then consent
and the proportion continuing for 3, 6, and 12 months to the
end of the study. We will report on the perspectives of service
users, carers, and mental health staff in relation to the frequency
of seeking help in relation to EWSs; the frequency in which a
family member/carer has sought help in response to EWSs, and
the frequency of clinical care that has changed in response to
EWSs at 3, 6, and 12 months.
Acceptability and Usability
For those randomized to EMPOWER, we will report the length
of time participants are willing to use the app and the number
completing >33% of EWS datasets. We will also report the
self-reported frequency of app use, frequency of sharing data
with the keyworker, frequency of sharing data with the family
member/carer, and frequency of accessing charts at 3, 6, and
12 months. We will also assess self-reported acceptability and
usability using an adapted version of the Mobile App Rating
Scale [55].
Safety—Adverse Events
Details of recording and reporting all adverse events is contained
in our Standard Operating Procedure for Adverse Events that
complies with Medical Devices Regulations 2002, ISO/FDIS
14155:2011 and Standards for Good Clinical Practice. An
adverse event is defined as serious if it (1) results in death, (2)
is a life-threatening illness or injury, (3) requires (voluntary or
involuntary) hospitalization or prolongation of existing
hospitalization, (4) results in persistent or significant disability
or incapacity, or (5) is a medical or surgical intervention required
to prevent any of the above, (6) leads to fetal distress, fetal
death, or consists of a congenital anomaly or birth defect, or (7)
is otherwise considered medically significant by the investigator.
We will record any adverse device effects (serious or otherwise)
arising from the EMPOWER algorithm. In addition, we will
measure all adverse effects arising from study procedures
including use of the EMPOWER app. We have prespecified
(but not limited) these to (1) increased fear of relapse or paranoia
associated with responding to questions in the EMPOWER app
and (2) increased worries about surveillance by psychiatric
services. We will also assess changes in fear of relapse using
the Fear of Recurrence Scale [18].
The relationship between the investigational medical device
and the occurrence of each adverse event will be assessed and
categorized. In consultation with the RA and the trial manager,
the chief investigator will use clinical judgment to determine
the relationship. Alternative causes, such as natural history of
the participant’s underlying condition, concomitant therapy,
and other risk factors, will be considered.
We also record medical device deficiencies, which is any
inadequacy of the EMPOWER medical device. These can
include malfunctions, end user errors, and inadequate labeling.
Performance
The following performance endpoints have been identified:
1. Each participant has the app successfully uploaded on a
mobile phone.
2. Each participant has personalized EWSs included in the
EMPOWER questionnaire.
3. Each participant receives a daily prompt to complete their
questionnaire.
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4. Participants receive an EMPOWER message each time they
complete the questionnaire.
5. Following 4 weeks of usage, the EMPOWER algorithm
calculates each of the participant’s individualized baseline
or variance of symptoms and experiences.
6. Participants can access charts of their symptoms and
experiences covering 1-week and 1-month time intervals.
7. Following completion of the questionnaire, participants’
data are transferred to the secure server.
8. Researchers access participants’ questionnaire responses
and generate charts to observe changes over time.
9. Researchers receive a record of alerts for each participant
and can record actions in relation to these alerts.
Candidate Outcomes
Candidate Primary Outcome
Data related to symptom change and possible relapse will be
extracted prospectively from electronic case notes by RAs.
Relapse is defined as (1) a return or exacerbation in psychotic
symptoms of at least moderate degree; (2) where symptoms
have lasted at least one week in duration, and there is evidence
of a decline in functioning or an increase in risk to self or others;
and (3) there is evidence of a clinical response from services.
Relapse criteria are summarized in Table 2.
Table 2. Early signs monitoring to prevent relapse in psychosis and promote well-being, engagement, and recovery relapse criteria.
Notes and definitionsCriteria
A return or exacerbation in psychotic symp-
toms of at least moderate degree; If present
score=1
• These are defined as first rank psychotic symptoms including hallucinations, delusions, thought
disorder and persecutory paranoia
• In line with Positive and Negative Syndrome Scale assessments, moderate severity means that
these occur at least occasionally or intrude on daily life to a moderate extent
AND Where symptoms have lasted at least 1
week in duration; If present score=1
• There was clear evidence that duration of psychotic symptoms occurred over at least 1 week
AND Where there is evidence of a decline in
functioning; If present score=1
• Includes a decline in one or more of the role performance areas identified from the Personal and
Social Performance Scale:
• Socially useful activities, including work and study (this should include cooperation with
household tasks, voluntary work, and useful hobbies, such as gardening)
• Personal and social relationships (this includes relationships with a partner or relatives and
broader social relationships)
• Self-care (personal hygiene, personal appearance, and dressing)
• General domains to consider are physical and psychological health care; lodging (area of residence
and living space care); contribution to household activities; participation in family life or resi-
dential/day-center life; intimate and sexual relationships; childcare; social network, friends, and
helpers; general interests; financial management; use of transport; coping skills in crisis; keeping
social rules
OR An increase in risk to self or others; If
present score=1
• Increase in risk to self includes deliberate self-injury and/or suicidal ideation that was clinically
significant in the investigator’s judgment. Evidence is required of either an increase in thoughts
or an intent to act upon such thoughts. These must occur within the context of the episode and
be accompanied by a service response. The service response can be reflected in that there is a
statement of increased risk, there is a note of discussing safety plans, or staff have ensured that
the participant has access to crisis contacts
• Increase in risk to others includes significant violent and aggressive behavior. This also includes
homicidal ideation, with evidence of intent to act upon this. Violent and aggressive behavior
should only be recorded as an increase in risk where there is evidence of a service response to
manage this behavior
AND There is evidence of a clinical response
from services; If present score for each of these
criteria=1 (Maximum=3)
• An increase or change in medication, increased home visits, or referral to crisis services
• Any hospital admission or imposition of a Community Treatment Order in response to psychosis
• Use of the mental health act to enforce an involuntary hospital admission
RAs who are not blinded to the treatment condition extracted
data from electronic case records to document all recorded
episodes of changes in psychotic symptoms, functioning, risk,
and clinical management. These episodes will provide the basis
for individual anonymized case vignettes that are submitted to
our independent and blinded adjudication panel. All vignettes
will be fully anonymized and any information relating to the
EMPOWER intervention will be concealed. This panel will
contain expert clinicians/researchers who will have the necessary
knowledge, experience, and skills to make independent blinded
judgments regarding relapse/exacerbation. The panel will
determine that a relapse event has occurred and will also rate
the severity of relapse on a 7-point scale based on the criteria
included in Table 2. We will report time to first relapse, type
of relapse (Relapse, Exacerbation, and Unspecified). We will
also report number (%) with (1) return or exacerbation in
psychotic symptoms, (2) duration of at least one week, (3)
reduction in functioning, (4) increase in risk, (5) change in
clinical management, (6) admission to hospital, and (7) use of
mental health act. We will report details of all relapse outcomes
across both groups. All participants will be assessed at each
follow-up point for the presence of any of these criteria
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described in Table 2, enabling us to calculate a mean severity
score across participants and allocated groups at each follow-up
point.
Candidate Secondary Outcomes
We will also assess changes in symptoms, substance use,
emotional distress, carer burden, service engagement, and
adherence and health-related quality of life.
1. Mental health status: The Positive and Negative Syndrome
Scale [56], Personal and Social Performance Scale [57],
and the Calgary Depression Scale for Schizophrenia [58]
will be completed with service user participants.
2. Substance use measures: Time line follow back for drugs
and alcohol [59]
3. Emotional distress: Hospital Anxiety and Depression Scale
[60] and the Personal Beliefs about Illness
Questionnaire-Revised [61].
4. Service engagement: The Service Attachment Scale [62]
and the Medication Adherence Rating Scale [63] will be
completed by service user participants.
5. Health Economics: EuroQol 5 Dimension 5 Level
(EQ-5D-5L) [64] and the Assessment of Quality of Life—8
Dimension (AQoL-8D) [65], the CarerQoL [66], and a
Resource Use Questionnaire (RUQ).
Candidate Mechanisms
Measures have been selected that map directly onto
hypothesized mechanisms of change and known predictors of
relapse. Mechanisms of service user benefit are operationalized
as improvements in personal recovery, empowerment, and
utilization of social support.
1. Recovery and self-efficacy: Questionnaire for Personal
Recovery [67] and the General Self-Efficacy Scale [68]
will be completed by service user participants.
2. Social and interpersonal context: Psychosis Attachment
Measure [69] and Perceived Criticism and Warmth Measure
adapted from the Perceived Criticism Measure (PCM) [70]
will be completed by service user participants.
Carer Outcomes
The Involvement Evaluation Questionnaire [71] will be
completed as a measure of carers worrying, tension, urging, and
supervision. A carer PCM adapted from the PCM described
above will be used as a measure of carers’ perspectives on
relationship quality.
We will also assess Carer Health Economic Outcomes using a
purposively designed RUQ, time cost questionnaire, the
EQ-5D-5L, and the CarerQol-7D.
Care Coordinator Outcomes
Participants care coordinators will complete the Service
Engagement Scale [72].
Process Evaluation
In line with recent MRC Guidance on process evaluation of
complex interventions [73], we will produce a logic model for
the EMPOWER intervention and conduct a process evaluation.
The process evaluation will be used to explore the ways in which
EMPOWER may operate to produce outcomes. Specifically, it
will focus on intervention fidelity, exposure, reach, context,
recruitment, retention, and contamination, as well as the
acceptability of study procedures. We will interview service
users, carers, mental health staff, and research staff to ensure a
multiperspective understanding of the intervention. We will
publish the protocol for the process evaluation elsewhere.
Sample Size
No formal sample size calculation is appropriate for this pilot
phase. The proposed sample size of up to 120 service users
across 40 care coordinators in 8 CMHSs is deemed to be
sufficient to establish feasibility and obtain parameters
(including the relevant ICCs for the cluster design) to inform
the design and size of a future definitive, pragmatic, multicenter,
and multinational cRCT.
Recruitment and Randomization
The unit of randomization is the CMHS (the cluster).
Participating CMHSs will be randomized within stratified pairs
to the EMPOWER Relapse Prevention Intervention or to
continue their usual approach to care. A statistician at the Centre
for Healthcare Randomised Trials (CHaRT) at the University
of Aberdeen will provide the allocation codes. The 2 clusters
in Australia form a single stratum. The 6 clusters in Glasgow
will be paired based on similarity of catchment area in terms of
social deprivation or CMHS type (eg, early intervention service).
Researchers will approach each eligible care coordinator and
seek their consent to participate in the trial. Before
randomization, consenting care coordinators will provide an
anonymized list of their current potentially eligible caseload of
people using services. This list will then be randomly ordered
by CHaRT. Researchers will then approach identified people
sequentially in blocks of up to 5 potentially eligible participants
and seek informed consent to participate in the study. If there
are further participants eligible for inclusion at the end of this
block, the researcher will move onto the next block of 5 (if
applicable). Care coordinators will provide participants with an
easy-to-read information leaflet about the study to enable
potential participants to express interest in finding out more
information. In Australia, information posters will be displayed
within staff areas of participating sites to inform care
coordinators of the study and provide contact details of RAs,
should they wish to participate.
We aim to approach and consent on an average of 3 participants
per care coordinator (giving a total of up to 120 potential
participants). Following consultation with the independent Data
Management and Ethics Committee (DMEC) and the Study
Steering Committee (SSC) in May 2018, these recruitment
objectives were amended to 86 participants. This was because
of a number of challenges to recruitment including (1) temporary
suspension of the study to apply for registration with the MHRA,
which delayed start up to recruitment, (2) comprehensive and
detailed screening of all potential trial participants, (3) delays
arising from care coordinators approaching potential
participants, and (4) high rates of turnover among care
coordinators. Following independent methodological and
statistical advice, there was clear guidance that the original
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feasibility aims will be met by the trial, and this change to
recruitment targets was approved by the funders. After
completing baseline assessments on all consenting service users
in care coordinators’ and CMHSs’ caseload, the Clinical Trials
Unit (CTU) at CHaRT will conduct randomization of the
CMHSs. For Australia, with just 2 clusters, this will be by
simple randomization by the CTU. For Glasgow, with 6 clusters,
the CTU will create 3 pairs of teams based on similarity of the
catchment area in terms of social deprivation (Carstairs) score
or CMHS type (eg, early intervention service). The CTU will
randomly allocate one member of the pair to the intervention,
and the remaining member will be allocated to control.
We will explore in this pilot phase the best method of randomly
allocating the clusters in the full trial, specifically to establish
what matching factors (if any, and/or if matching at all is
appropriate, methodologically) are suitable. Any violations of
the study protocol will be recorded and reported to the Research
Ethics Committee, SSC, and the independent DMEC.
Statistical Analysis
A full statistical analysis plan will be written before (and
published on the CHaRT website) any analysis is being
undertaken. All analyses will be carried out using the
intention-to-treat principle with data from all participants
included in the analysis including those who do not complete
the intervention. Every effort will be made to follow up all
participants in both arms for research assessments. The analysis
will follow the guidelines of the CONSORT statement for
clustered randomized trials and recommendations for the
analysis of clustered randomized trials when presenting and
analyzing the data. Here, we have potentially repeated measures
on individual patients nested within care coordinators who are
nested within teams (the unit of randomization) who are in turn
nested within region (Australia and the United Kingdom or
possibly to be known as Scotland). The analysis will adjust for
these factors using appropriate random (service user, if relevant;
care coordinator; and team) and fixed (region) effects. The trial
statistician will remain blind until the main analyses are
complete. Baseline characteristics of the study population will
be summarized separately within each randomized group.
Baseline characteristics will also be presented for drop-outs and
completers within each treatment group.
A full Health Economic Statistical Analysis Plan will be written
before any analysis is being undertaken. As part of the within
trial economic evaluation, we propose to test 2 health-related
quality of life measures (which can be used to assess
Quality-Adjusted Life Years), the EQ-5D-5L, and the AQoL-8D
in the feasibility trial. Although the EQ-5D-5L is very
commonly used in the United Kingdom and Australian context,
its sensitivity and appropriateness in people with schizophrenia
has been seriously questioned [74]. The AQoL-8D is a newer
HRQoL measure and was developed to be sensitive to the
domains of quality of life that are important to people with
mental health problems. A RUQ to capture costs incurred will
also be tested. This questionnaire will need to be appropriate
to both the United Kingdom and Australian context but may
require some system-specific modules for services, which differ
between the 2 settings.
Data Sharing
Data generated by this research will be made available as soon
as possible based upon reasonable request to the study chief
investigator.
Ethics Approval
West of Scotland Research Ethics Service (GN16MH271 Ref:
REC/16/WS/0042) and Melbourne Health (HREC/15/MH/344).
Results
Recruitment to the trial began in September 2017, and follow-up
of participants was completed in July 2019. The database lock
was in July 2019, followed by analysis and disclosing of group
allocation.
Discussion
Relapse among people with a diagnosis of schizophrenia is a
major contributor to poorer outcomes in terms of greater
symptom severity, distress, and risk of a range of adverse
outcomes including coercion into care, self-harm, and suicide
[8-12]. People diagnosed with schizophrenia worry about
relapse, and this is linked to feelings of anxiety, shame,
depression, and shorter time to relapse [18]. Relapse contributes
to carers’ experiences of distress and worry and has been linked
to greater needs for continuity of communication with mental
health care professionals [75]. Mental health staff are concerned
about the impact of relapse on service users and carers, but the
impact on their roles are also considerable in terms of
responding to crises and increased risk [24]. These sources of
strain place relationships under significant pressure, which can
break down communication, anticipatory care, and shared
decision making especially in the context of EWSs of relapse.
This can potentially result in loss of collaboration, increased
risk of disengagement, and greater use of coercion, thus
confirming many of the fearful and threat-based expectations
held by service users, carers, and, arguably, the staff [25].
On the basis of our theoretical model outlined earlier, we have
developed an intervention that blends a digital intervention with
peer support, with triage of increased risk of relapse to prompt
early interventions that are attuned to needs of service users.
Our approach uses digital technology to enable service users to
monitor the ebb and flow of emotional well-being in daily life
and utilizes an algorithm to deliver messages to enhance
attunement, awareness, curiosity, and self-management in
response to changes in well-being. In our theory, the blending
of digital with peer support is important to cultivate helpful
conversations to promote greater autonomy, empowerment, and
recovery. We anticipate that conversations focused around the
ebb and flow of changes in well-being in daily life can also
increase opportunities for earlier help seeking, collaboration,
and shared decision making in the event of possible EWSs
facilitated by clinician triage into a relapse prevention pathway
embedded in mental health services.
The EMPOWER trial will deliver the protocol for a blended
digital intervention and will establish the feasibility of running
a definitive cRCT. We will establish the safety, acceptability,
JMIR Res Protoc 2020 | vol. 9 | iss. 1 | e15058 | p. 13https://www.researchprotocols.org/2020/1/e15058
(page number not for citation purposes)
Gumley et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
usability, and performance parameters of the EMPOWER
intervention. We will learn how to optimize the identification,
consent, and follow-up of potentially eligible participants. We
will establish the feasibility of measuring and collecting our
candidate primary, secondary, and mechanistic outcomes.
However, in its own right, our study has a number of important
broader implications for digital health interventions for people
diagnosed with schizophrenia and psychosis. Our mobile phone
app will be available for people to use for up to 1 year on a daily
basis. To our knowledge, this will be the longest RCT of a
mobile phone app in psychosis to date. In addition, the algorithm
that underpins the assessment of ebb and flow is, to our
knowledge, the first mental health app to be registered as a
medical device trial (CI/2017/0039) by the United Kingdom’s
Medicines and Healthcare products Regulatory Agency.
We will also establish and report the rater reliability of our a
priori definition of relapse that has been informed by our
theoretical model [18] that underpins the intervention. In studies
of relapse in schizophrenia, there is a lack of consensus as to
the definitions of relapse measurement [76], very often studies
actually fail to report their definitions of relapse [77], and, to
our knowledge, none have ever consulted people with lived
experience of psychosis on how relapse is measured and defined.
Our approach to relapse assessment aims to address these major
shortcomings in the literature making the theory, rationale,
measurement, and interrater reliability of our definition explicit.
In addition, our approach will enable us to report time to relapse,
severity of relapse, and mean severity scores across groups at
each follow-up timepoint.
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